For Physicians. By Physicians.™
For Physicians. By Physicians.™
Neuraminidase inhibitors are antiviral drugs commonly used for the flu such as Oseltamivir (Tamiflu) or Zanamivir (Relenza). This study by Graner et al. (BMJ, 2017) aimed to explore any relationship associated with neuraminidase inhibitors and adverse neonatal outcomes, such as low birth weight, preterm birth, low Agpar score, stillbirth, neonatal mortality or morbidity, and congenital malformations.
Observational Cohort Study and Meta-Analysis
5,824 women who had taken neuraminidase inhibitors during pregnancy and 692,232 women who had not were surveyed along with their infants. Infants who had been exposed to neuraminidase inhibitors in utero did not have increased rates of any of the adverse neonatal outcomes or congenital malformations even when medication was taken in the first trimester. These findings are aligned with previous studies that likewise did not find an association between this class of drugs and adverse neonatal outcomes.
Please log in to ObGFirst to access this page
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
